Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darolutamide versus placebo added to ADT and docetaxel in metastatic hormone-sensitive prostate cancer
NL-OMON45459Phase 3Active, not recruiting
- Sponsor
- Bayer
- Start
- Nov 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Darolutamide + ADT + docetaxel with Placebo + ADT + docetaxel (2 arms). Primary endpoint: Overall survival. Started Nov 2016; status: active, not recruiting.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON45459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45459.